Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash & Equivalents (2020 - 2024)

Immuneering has reported Cash & Equivalents over the past 5 years, most recently at $45.2 million for Q3 2024.

  • Quarterly results put Cash & Equivalents at $45.2 million for Q3 2024, down 33.56% from a year ago — trailing twelve months through Sep 2024 was $45.2 million (down 33.56% YoY), and the annual figure for FY2023 was $59.4 million, down 18.22%.
  • Cash & Equivalents for Q3 2024 was $45.2 million at Immuneering, down from $59.7 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IMRX hit a ceiling of $106.9 million in Q3 2021 and a floor of $37.1 million in Q4 2020.
  • Median Cash & Equivalents over the past 5 years was $72.6 million (2022), compared with a mean of $70.8 million.
  • Biggest five-year swings in Cash & Equivalents: surged 101.91% in 2021 and later crashed 42.58% in 2024.
  • Immuneering's Cash & Equivalents stood at $37.1 million in 2020, then soared by 101.91% to $74.9 million in 2021, then decreased by 3.01% to $72.6 million in 2022, then decreased by 18.22% to $59.4 million in 2023, then decreased by 23.9% to $45.2 million in 2024.
  • The last three reported values for Cash & Equivalents were $45.2 million (Q3 2024), $59.7 million (Q2 2024), and $66.3 million (Q1 2024) per Business Quant data.